Replimune group, Inc. (NASDAQ: REPL) is leveraging the power of its proprietary Immulytic platform to create a leading-edge oncolytic immunotherapy program that can generate a patient-specific local as well as systemic immune response. The therapies not only fight against the current cancer but also eliminate...
There is a lot of buzz around Acer Therapeutics (NASDAQ: ACER) resulting in the stock zooming skywards. The sudden interest in the company is based on rumors that the Company is likely to be acquired by Relief Therapeutics (OTCQB: RLFTF), a biopharmaceutical company whose lead...
Albireo Pharma, Inc. (NASDAQ: ALBO) a clinical-stage company targeting rare liver diseases, announced the acceptance of its New Drug Application (NDA) for odevixibat, a once-daily, non-systemic IBAT, intended for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The candidate is also...
